Single versus Double Autologous Stem-Cell Transplantation for Multiple Myeloma
The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Abstract
BACKGROUND: We conducted a randomized trial of the treatment of multiple myeloma with high-dose chemotherapy followed by either one or two successive autologous stem-cell transplantations. METHODS: At the time of diagnosis, 399 previously untreated patients under the age of 60 years were randomly assigned to receive a single or double transplant. RESULTS: A complete or a very good partial response was achieved by 42 percent of patients in the single-transplant group and 50 percent of patients in the double-transplant group (P=0.10). The probability of surviving event-free for seven years after the diagnosis was 10 percent in the single-transplant group and 20 percent in the double-transplant group (P=0.03). The estimated overall seven-year survival rate was 21 percent in the single-transplant group and 42 percent in the double-transplant group (P=0.01). Among patients who did not have a very good partial response within three months after one transplantation, the probability of surviving seven years was 11 percent in the single-transplant group and 43 percent in the double-transplant group (P<0.001). Four factors were significantly related to survival: base-line serum levels of beta2-microglobulin (P<0.01) and lactate dehydrogenase (P<0.01), age (P<0.05), and treatment group (P<0.01). CONCLUSIONS: As compared with a single autologous stem-cell transplantation after high-dose chemotherapy, double transplantation improves overall survival among patients with myeloma, especially those who do not have a very good partial response after undergoing one transplantation.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In earlier randomized trials, an improvement in OS was seen in two studies,132,133 but other studies failed to show such an improvement.134,135”
From Multiple myeloma: 2024 update on diagnosis, risk-stratification, and management (2024) · cites this paper as [132]
Citations
Cites
A Phase 2 Study of Bortezomib in Relapsed, Refractory Myeloma
Richardson, P. G., Barlogie, B., Berenson, J., Singhal, S., Jagannath, S., Irwin, D., Rajkumar, S. V., Srkalovic, G., Alsina, M., Alexanian, R., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa030288 · Cited by 2,632
Antitumor Activity of Thalidomide in Refractory Multiple Myeloma
Singhal, S., Mehta, J., Desikan, R., Ayers, D., Roberson, P., Eddlemon, P., Munshi, N., Anaissie, E., Wilson, C., Dhodapkar, M., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199911183412102 · Cited by 2,575
Attal, M., Harousseau, J.-L., Stoppa, A.-M., Sotto, J.-J., Fuzibet, J.-G., Rossi, J.-F., Casassus, P., Maisonneuve, H., Facon, T., Ifrah, N., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199607113350204 · Cited by 2,548
Self-citationHigh-Dose Chemotherapy with Hematopoietic Stem-Cell Rescue for Multiple Myeloma
Child, J. A., Morgan, G. J., Davies, F. E., Owen, R. G., Bell, S. E., Hawkins, K., Brown, J., Drayson, M. T., & Selby, P. J. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa022340 · Cited by 1,768
BladÉ, J., Samson, D., Reece, D., Apperley, J., BJÖrkstrand, B., Gahrton, G., Gertz, M., Giralt, S., Jagannath, S., Vesole, D., et al. (1998) · British Journal of Haematology · doi:10.1046/j.1365-2141.1998.00930.x · Cited by 1,519
Moreau, P. (2002) · Blood · doi:10.1182/blood.v99.3.731 · Cited by 564
Fermand, J.-P., Ravaud, P., Chevret, S., Divine, M., Leblond, V., Belanger, C., Macro, M., Pertuiset, E., Dreyfus, F., Mariette, X., et al. (1998) · Blood · doi:10.1182/blood.v92.9.3131 · Cited by 542
Total Therapy With Tandem Transplants for Newly Diagnosed Multiple Myeloma
Barlogie, B., Jagannath, S., Desikan, K. R., Mattox, S., Vesole, D., Siegel, D., Tricot, G., Munshi, N., Fassas, A., Singhal, S., et al. (1999) · Blood · doi:10.1182/blood.v93.1.55 · Cited by 472
(1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.12.3832 · Cited by 433
INTENSIVE TREATMENT OF MULTIPLE MYELOMA AND CRITERIA FOR COMPLETE REMISSION
Gore, M. E., Viner, C., Meldrum, M., Bell, J., Milan, S., Zuiable, A., Slevin, M., Selby, P. J., Clark, P. I., Millar, B., et al. (1989) · The Lancet · doi:10.1016/s0140-6736(89)91548-1 · Cited by 190
Research works printed but not linked: 7
- Barlogie B, 1991, Bone Marrow Transplant, 7, 71
- Fermand J-P, 1999, Blood, 94, 396a
- Blade J, 2001, Blood, 98, 815a
- Palumbo A, 2001, Blood, 98, 849a
- Fermand J-P, 2001, Blood, 98, 815a
- Richardson P, 2002, Blood, 100, 104a
- Sirohi B, 2002, Bone Marrow Transplant, 29, S12
Cited by
Items 401–500 of 987
Therapeutic approaches for newly diagnosed multiple myeloma patients in the era of novel drugs
Morabito, F., Gentile, M., Mazzone, C., Bringhen, S., Vigna, E., Lucia, E., Recchia, A. G., Raimondo, F. D., Musto, P., & Palumbo, A. (2010) · European Journal Of Haematology · doi:10.1111/j.1600-0609.2010.01472.x · Cited by 20
“(two sequential transplants) than from a single transplantation, at least for patients who had not achieved complete response (CR) (34).”
BackgroundRelapsed multiple myeloma: who benefits from salvage autografts?
Chow, A. W. S., Lee, C. H. S., Hiwase, D., To, L. B., & Horvath, N. (2012) · Internal Medicine Journal · doi:10.1111/j.1445-5994.2012.02867.x · Cited by 20
Auner, H. W., Mazzarella, L., Cook, L. B. M., Szydlo, R., Saltarelli, F., Pavlů, J., Bua, M., Giles, C. M., Apperley, J. F., & Rahemtulla, A. (2010) · Bone Marrow Transplantation · doi:10.1038/bmt.2010.141 · Cited by 20
Rosiñol, L., García‐Sánz, R., Lahuerta, J. J., Hernandez-Garcia, M., Granell, M., de la Rubia, J., Oriol, A., Hernández-Ruíz, B., Rayón, C., Navarro, I., et al. (2011) · Haematologica · doi:10.3324/haematol.2011.051441 · Cited by 20
“In addition, tandem autologous transplants have been shown to be of benefit for patients failing to achieve at least very good partial response with the first transplant.(11-12) Whether autologous SCT is beneficial for the majority of patients or the overall benefit comes from certain subsets of patients is still an u…”
BackgroundAhmad, I., LeBlanc, R., Cohen, S., Lachance, S., Kiss, T. L., Sauvageau, G., Roy, D.-C., Busque, L., Delisle, J., Bambace, N. M., et al. (2015) · Bone Marrow Transplantation · doi:10.1038/bmt.2015.319 · Cited by 21
Paviglianiti, A., Xavier, E., Ruggeri, A., Céballos, P., Deconinck, É., Cornelissen, J. J., Nguyen‐Quoc, S., Maillard, N., Sanz, G. F., Rohrlich, P., et al. (2016) · Haematologica · doi:10.3324/haematol.2015.138917 · Cited by 21
Safety Outcomes for Autologous Stem Cell Transplant in Multiple Myeloma
Gertz, M. A., Buadi, F. K., Hayman, S. R., Lacy, M. Q., Dispenzieri, A. A., Dingli, D., Gonsalves, W. I., Kumar, S. K., Kapoor, P., Kourelis, T., et al. (2018) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2017.09.012 · Cited by 20
On behalf of the Swiss Blood Stem Cell Transplantation Registry, Ghilardi, G., Pabst, T., Jeker, B., Müller, R., Cairoli, A., Müller, A. M. S., Bargetzi, M. J., Hitz, F., Baldomero, H., et al. (2018) · Bone Marrow Transplantation · doi:10.1038/s41409-018-0379-y · Cited by 21
Hart, C. A., Grassinger, J., Andreesen, R., & Hennemann, B. (2008) · Bone Marrow Transplantation · doi:10.1038/bmt.2008.315 · Cited by 20
Five decades of therapy for multiple myeloma: a paradigm for therapeutic models
Kyle, R. A. (2005) · Leukemia · doi:10.1038/sj.leu.2403728 · Cited by 20
An Update of the Management of Multiple Myeloma: The Changing Landscape
Reece, D. E. (2005) · Hematology · doi:10.1182/asheducation-2005.1.353 · Cited by 20
Allogeneic stem cell transplantation in multiple myeloma: immunotherapy and new drugs
Festuccia, M. B., Martino, M. V., Ferrando, F., Messina, G., Moscato, T., Fedele, R., Boccadoro, M., Giaccone, L., & Bruno, B. (2015) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2015.1036735 · Cited by 20
“Despite the introduction of the so-called new drugs, single or double auto-SCT remains part of standard upfront treatment in patients up to the age of 65 [21-24], whereas the upfront use of RIC allo-SCT has practically been abandoned and remains to be undefined.”
Biran, N., Ely, S. A., & Chari, A. (2014) · Current Hematologic Malignancy Reports · doi:10.1007/s11899-014-0237-y · Cited by 19
“The clinical significance of achieving a CR by PEP/IFE has been well described [1, 3, 16–22], perhaps most convincingly from two large meta-analyses in both the transplant-eligible and transplant-ineligible population that demonstrated a correlation between the depth response by PEP/IFE with long-term survival comes […”
Ludek, P., Šváchová, H., Adam, Z., Almáši, M., Kralova, D., Büchler, T., Kovářová, L., Krejčí, M., Michálek, J., Penka, M., et al. (2009) · European Journal Of Haematology · doi:10.1111/j.1600-0609.2009.01396.x · Cited by 20
Wirk (2013) · Journal of Clinical Medicine Research · doi:10.4021/jocmr1274w · Cited by 19
“In a sub analysis of 2 prospective studies, tandem autoHCT improved OS in those who did not achieve at least VGPR after autoHCT1 [15, 16].”
Considerations in the treatment of multiple myeloma: a consensus statement from Italian experts
Patriarca, F. F., Petrucci, M. T., Bringhen, S., Baldini, L., Caravita, T., Corradini, P., Corso, A., Raimondo, F. D., Falcone, A. P., Ferrara, F., et al. (2008) · European Journal Of Haematology · doi:10.1111/j.1600-0609.2008.01179.x · Cited by 21
“The Inter-groupe Francophone du Myelome (IFM) was the first to conduct a randomised trial comparing single and double ASCT and showed significant improvement in both EFS and OS in the double ASCT arm (41).”
BackgroundDiagnosis and therapy of multiple myeloma
Palumbo, A. P., & Cerrato, C. (2013) · The Korean Journal of Internal Medicine · doi:10.3904/kjim.2013.28.3.263 · Cited by 21
“Considering that achieving a deeper response is associated with a longer OS [30-32], tandem ASCT should be suggested in patients who fail to achieve at least a very good partial response (VGPR) after the first ASCT [25,26,28,32,33].”
BackgroundAugmenting Autologous Stem Cell Transplantation to Improve Outcomes in Myeloma
Maybury, B. D., Cook, G., Pratt, G., Yong, K., & Ramasamy, K. (2016) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2016.06.004 · Cited by 22
Engelhardt, M. M., Müller, A. M. S., Maier, W., & Wäsch, R. (2005) · Leukemia · doi:10.1038/sj.leu.2403723 · Cited by 19
“dtd"[ ]> TO THE EDITOR Molecular detection of novel molecular targets in multiple myeloma (MM) has given rise to exciting new therapeutic options for MM patients including the use of high-dose dexamethasone, thalidomide, revimid, bortezomib and early single or double autologous stem-cell transplantation”
BackgroundChong, Y. P., Kim, S., Ko, O. B., Koo, J. E., Lee, D., Park, S. H., Park, S. J., Lee, D., Kim, S. W., & Suh, C. (2008) · Journal of Korean Medical Science · doi:10.3346/jkms.2008.23.5.819 · Cited by 19
“9) Cycles of prior chemotherapy 4 (3-5) 3 (2-31)”
BackgroundRecent advances in the mangement of multiple myeloma.
Kumar, L., Vikram, P., & Kochupillai, V. (2006) · PubMed · Cited by 29
Progress in hematopoietic stem cell transplantation in multiple myeloma
Gahrton, G. (2005) · Current Opinion in Hematology · doi:10.1097/01.moh.0000182836.40779.e7 · Cited by 19
Costa, B. A., Mouhieddine, T. H., Ortiz, R. J., & Richter, J. (2023) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2023.104040 · Cited by 18
How to treat a newly diagnosed young patient with multiple myeloma
Miguel, J. F. S., & Mateos, M. (2009) · Hematology · doi:10.1182/asheducation-2009.1.555 · Cited by 21
Özsan, G. H., Micallef, I. N., Dispenzieri, A. A., Kumar, S. K., Lacy, M. Q., Dingli, D., Hayman, S. R., Buadi, F. K., Wolf, R. C., Gastineau, D. A., et al. (2011) · American Journal of Hematology · doi:10.1002/ajh.22179 · Cited by 18
“For MM patients who fail to achieve a very good partial response or complete response with the first transplant, a second (tandem) transplant provides a survival benefit [12].”
BackgroundFenchel, M. C., Konaktchieva, M. N., Weisel, K. C., Kraus, S., Brodoefel, H., Claussen, C. D., & Horger, M. (2010) · European Radiology · doi:10.1007/s00330-010-1870-z · Cited by 18
“The treatment of myeloma has undergone major changes in the last decade [6, 7]. Recently, novel drug classes targeting both myeloma and its microenvironment have shown high anti-proliferative activity and reduced toxic effects [8, 9]. Bortezomib, a proteasome inhibitor, improves time to progression and survival rates…”
BackgroundLemoli, R. M., D’Addio, A., Marotta, G., Pezzullo, L., Zuffa, E., Montanari, M., Vivo, A. D., Bonini, A., Galieni, P., Carella, A. M., et al. (2009) · Bone Marrow Transplantation · doi:10.1038/bmt.2009.235 · Cited by 18
Zaucha, R., Buckner, D. C., Barnett, T., Holmberg, L., Gooley, T. A., Hooper, H., Maloney, D. G., Appelbaum, F. R., & Bensinger, W. (2005) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2005.06.005 · Cited by 18
Barlogie, B., Zangari, M., Bolejack, V., Hollmig, K. A., Anaissie, E. J., van Rhee, F., Pineda‐Roman, M., Mohiuddin, A., Crowley, J. J., & Tricot, G. J. K. (2006) · Clinical Lymphoma & Myeloma · doi:10.3816/clm.2006.n.027 · Cited by 19
Bortezomib for the treatment of multiple myeloma
Grosicki, S., Barchnicka, A., Jurczyszyn, A. J., & Grosicka, A. (2014) · Expert Review of Hematology · doi:10.1586/17474086.2014.899144 · Cited by 20
Feasibility and outcome of tandem stem cell autotransplants in multiple myeloma.
Galli, M., Nicolucci, A., Valentini, M., Belfiglio, M., Delaini, F., Crippa, C., Barbui, A. M., Giussani, U., Rambaldi, A., & Barbui, T. (2005) · PubMed · Cited by 18
Carlo‐Stella, C., Guidetti, A., Nicola, M. D., Lavazza, C., Cleris, L., Sia, D., Longoni, P. D., Milanesi, M., Magni, M., Nagy, Z. A., et al. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-3744 · Cited by 18
“Tandem autotransplantation has significantly increased both overall and event-free survival ( 43 , 44); however, due to age restrictions, its feasibility is limited to a small subset of young MM patients.”
BackgroundGratwohl, A. A., Baldomero, H., Labar, B., Apperley, J. F., & Urbano-Ispizúa, Á. (2004) · PubMed · Cited by 18
Bug, G., Atta, J., Klein, S., Hertenstein, B., Bergmann, L., Boehrer, S., Mousset, S., Hoelzer, D. F., & Martin, H. (2005) · Annals of Hematology · doi:10.1007/s00277-005-1075-8 · Cited by 18
“HD-Mel with PBSC support has been used extensively for the treatment of lymphoid malignancies, such as multiple myeloma [1] and relapsed or refractory lymphoma [16], as well as for conditioning in consolidating transplants for acute lymphoblastic leukaemia [18].”
BackgroundMethodStem cell transplantation for multiple myeloma: current and future status
Giralt, S. (2012) · Hematology · doi:10.1179/102453312x13336169156258 · Cited by 17
Jónsdóttir, G., Björkholm, M., Turesson, I., Hultcrantz, M. L., Diamond, B. T., Porwit‐MacDonald, A., Landgren, O., & Kristinsson, S. Y. (2021) · European Journal Of Haematology · doi:10.1111/ejh.13650 · Cited by 18
Advances in the Autologous and Allogeneic Transplantation Strategies for Multiple Myeloma
Nishihori, T., & Alsina, M. (2011) · Cancer Control · doi:10.1177/107327481101800406 · Cited by 20
Autologous stem cell transplantation in patients with high‐risk plasmacytoma
Jantunen, E., Koivunen, E., Putkonen, M., Siitonen, T., Juvonen, E., & Nousiainen, T. (2005) · European Journal Of Haematology · doi:10.1111/j.1600-0609.2004.00404.x · Cited by 17
“Although the remission status of these patients is sometimes difficult to judge, this figure seems to be higher than the remission frequency with single or tandem ASCT in patients with MM (1, 2, 15, 16).”
BackgroundMcCarthy, P. L., Einsele, H., Attal, M., & Giralt, S. (2014) · Expert Review of Hematology · doi:10.1586/17474086.2014.878645 · Cited by 17
“A single versus tandem AHSCT was conducted by the IFM and for patients who attained less than a very good partial response (VGPR), a second AHSCT was found to be beneficial [21].”
MethodSelf-citationPedrazzoli, P., Martino, M. V., Delfanti, S., Generali, D., Rosti, G., Bregni, M., Lanza, F., & on behalf of the European Group for Blood and Marrow Transplantation (EBMT), S. T. W. P. (2015) · JNCI Monographs · doi:10.1093/jncimonographs/lgv010 · Cited by 17
Role of stem cell transplant and maintenance therapy in plasma cell disorders
McCarthy, P. L., & Holstein, S. A. (2016) · Hematology · doi:10.1182/asheducation-2016.1.504 · Cited by 18
Nunnelee, J. S., Cottini, F., Zhao, Q., Faisal, M. S., Elder, P., Rosko, A. E., Bumma, N., Khan, A., Devarakonda, S. S., Benson, D. M., et al. (2022) · Cancers · doi:10.3390/cancers14092277 · Cited by 18
Serum M‐spike and transplant outcome in patients with multiple myeloma
Dingli, D., Pacheco, J. M., Dispenzieri, A. A., Hayman, S. R., Kumar, S. K., Lacy, M. Q., Gastineau, D. A., & Gertz, M. A. (2007) · Cancer Science · doi:10.1111/j.1349-7006.2007.00499.x · Cited by 17
Musto, P., Falcone, A. P., Sanpaolo, G., Guglielmelli, T., Zambello, R., Balleari, E., Catalano, L., Spriano, M., Cavallo, F., Sala, A. L., et al. (2005) · Leukemia Research · doi:10.1016/j.leukres.2005.06.027 · Cited by 17
“Single or tandem autologous stem cell transplantation AuSCT) is extensively used as front-line therapy in multile myeloma (MM) [1–3].”
Stella-Holowiecka, B., Czerw, T., Holowiecka-Goral, A., Giebel, S., Wojnar, J., & Hołowiecki, J. (2007) · Transplantation Proceedings · doi:10.1016/j.transproceed.2007.08.052 · Cited by 17
Neri, P. E., Yasui, H., Hideshima, T., Tassone, P., Raje, N. S., Catley, L. P., Ishitsuka, K., Blotta, S., Kiziltepe, T., Ocio, E. M., et al. (2006) · British Journal of Haematology · doi:10.1111/j.1365-2141.2006.06122.x · Cited by 18
“…with glucocorticoids, alkylating agents, anthracyclines (Gregory et al, 1992) and high-dose chemotherapy combined with stem cell transplantation (Attal et al, 2003; Child et al, 2003; Kyle & Rajkumar, 2004), multiple myeloma (MM) remains incurable due to intrinsic and acquired drug resistance…”
BackgroundTreatment advances in multiple myeloma
Tricot, G. J. K., Barlogie, B., & van Rhee, F. (2004) · British Journal of Haematology · doi:10.1111/j.1365-2141.2004.04851.x · Cited by 17
Current Standards for First-Line Therapy of Multiple Myeloma
Jagannath, S. (2007) · Clinical Lymphoma & Myeloma · doi:10.3816/clm.2007.s.024 · Cited by 18
Martino, M. V., Console, G., Callea, V., Stelitano, C. C., Massara, E., Irrera, G., Messina, G., Morabito, F., & Iacopino, P. (2006) · European Journal Of Haematology · doi:10.1111/j.1600-0609.2006.00774.x · Cited by 16
The Role of High-Dose Therapy With Autologous Stem Cell Support in the Era of Novel Agents
Attal, M., & Harousseau, J. (2009) · Seminars in Hematology · doi:10.1053/j.seminhematol.2009.02.006 · Cited by 18
Self-citationEmerging biological insights and novel treatment strategies in multiple myeloma
Gentile, M., Recchia, A. G., Mazzone, C., & Morabito, F. (2012) · Expert Opinion on Emerging Drugs · doi:10.1517/14728214.2012.713345 · Cited by 19
“The benefit of tandem versus single ASCT still remains unclear [72,73].”
BackgroundSauer, S., Erdmann, K., Jensen, A. D., Wennmann, M., Pavel, P., Jordan, K., Schmitt, A., Kriegsmann, M., Wuchter, P., Goldschmidt, H., et al. (2021) · Transplantation and Cellular Therapy · doi:10.1016/j.jtct.2021.06.025 · Cited by 16
Multiple myeloma: ESMO Clinical Recommendations for diagnosis, treatment and follow-up
Harousseau, J., & Dreyling, M. H. (2008) · Annals of Oncology · doi:10.1093/annonc/mdn088 · Cited by 18
Self-citationCosta, B. A., Mouhieddine, T. H., & Richter, J. R. (2022) · Targeted Oncology · doi:10.1007/s11523-022-00897-8 · Cited by 21
“Later, further studies supported the alternative of reserving ASCT for the first disease relapse [95] and the possibility of a second peripheral blood stem cell (PBSC) infusion as part of salvage therapy in selected cases [96].”
ResultVogl, D. T., Liu, S. V., Chong, E. A., Luger, S. M., Porter, D. L., Schuster, S. J., Tsai, D. E., Perl, A. E., Loren, A. W., Goldstein, S. C., et al. (2007) · American Journal of Hematology · doi:10.1002/ajh.21038 · Cited by 16
Murakami, H., Shimizu, K., Sawamura, M., Suzuki, K., Sugiura, I., Kosugi, H., Shimazaki, C., Taniwaki, M., Abe, M., & Takagi, T. (2009) · International Journal of Hematology · doi:10.1007/s12185-009-0314-5 · Cited by 16
“The median overall survival has been improved by high-dose chemotherapy with autologous stem cell transplantation (ASCT) [ 1 ], as well as by the emergence of novel therapies, which improved post-relapse survival and overall survival as well [2].”
BackgroundAn old drug with a new future: bendamustine in multiple myeloma
Gentile, M., Recchia, A. G., Mazzone, C., Vigna, E., Martino, M. V., Morabito, L., Lucia, E., Bossio, S., Stefano, L. D., Granata, T., et al. (2013) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2013.837885 · Cited by 17
“Moreover, the benefit of tandem versus single ASCT has also been questioned [56,57].”
BackgroundŞahin, U., & Demirer, T. (2017) · Journal of Clinical Apheresis · doi:10.1002/jca.21591 · Cited by 18
“[9] Attal M, Harousseau JL, Facon T, InterGroupe Francophone du M, et al.”
BackgroundGarcía‐Sánz, R., Mateos, M., & Miguel, J. F. S. (2007) · Medicina Clínica · doi:10.1157/13107365 · Cited by 36
Rodriguez, A. L., Tariman, J. D., Enecio, T., & Estrella, S. M. (2007) · Clinical journal of oncology nursing · doi:10.1188/07.cjon.579-589 · Cited by 16
“This article discusses standard SCT in patients with MM, some of the newer transplantation strategies (e.g., tandem ASCT, reduced-intensity nonmyeloablative allogeneic SCT) and their implications for nursing.”
BackgroundPerotti, C. G., Fante, C. D., Viarengo, G., Perlini, S., Vezzoli, M., Rodi, G., Palo, A., Bergamaschi, P., & Salvaneschi, L. (2005) · Transfusion · doi:10.1111/j.1537-2995.2005.00597.x · Cited by 16
Treatment of multiple myeloma: An emphasis on new developments
Kyle, R. A., & Rajkumar, S. V. (2006) · Annals of Medicine · doi:10.1080/07853890500472078 · Cited by 16
Collection, Cryostorage, Transplantation, and Disposal of Hematopoietic Stem Cell Products
Kriegsmann, K., Wack, M., Pavel, P., Schmitt, A., Kriegsmann, M., Bruckner, T. M., Müller‐Tidow, C., & Wuchter, P. (2018) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2018.09.013 · Cited by 15
Long-term survival of patients with resistant lymphoma treated with tandem stem cell transplant
Ahmed, T., Rashid, K., Waheed, F., Kancherla, R., Qureshi, Z., Hoang, A., Richter, J. R., Ali, M., Goldberg, R., Liu, D., et al. (2004) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428190400019826 · Cited by 15
Martino, M. V., Bottini, A., Rosti, G., Generali, D., Secondino, S., Barni, S., Maisano, R., Lanza, F., Castagna, L., & Pedrazzoli, P. (2012) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2012.721767 · Cited by 15
“malignancies including multiple myeloma [85] and germ cell tumors [86], and in the GITMO retrospective analysis in HR BC [87].”
BackgroundBaumann, P., Müller, K., Mandl–Weber, S., Leban, J. J., Doblhofer, R., Ammendola, A., Baumgartner, R., Oduncu, F. S., & Schmidmaier, R. (2009) · British Journal of Haematology · doi:10.1111/j.1365-2141.2008.07570.x · Cited by 15
“Only dose escalation of melphalan enabled by autologous stem cell transplantation led to significant prolongation of overall survival (Attal et al, 1996, 2003; Barlogie et al, 1999; Child et al, 2003; Palumbo et al, 2004).”
BackgroundSamaras, P., Blickenstorfer, M., Siciliano, R. D., Haile, S. R., Buset, E. M., Petrausch, U., Mischo, A., Honegger, H., Schanz, U., Stüssi, G., et al. (2010) · Annals of Hematology · doi:10.1007/s00277-010-1036-8 · Cited by 15
“Autologous peripheral blood stem cell transplantation (APBSCT) is an established treatment modality for patients with multiple myeloma (MM) [1, 2].”
BackgroundChow, E. J., Rao, K. V., Wood, W. A., Covington, D. L., Armistead, P. M., Coghill, J. M., Serody, J. S., Gabriel, D. A., Jamieson, K. J., Park, Y. A., et al. (2014) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2014.03.023 · Cited by 15
“INTRODUCTION High-dose chemotherapy followed by autologous stem cell transplant (ASCT) remains an essential treatment modality in efforts to achieve a durable complete remission for patients with non-Hodgkin’s lymphoma (NHL), Hodgkin’s disease, and multiple myeloma (MM) [1,2].”
BackgroundBenevolo, G., Larocca, A., Gentile, M., Pregno, P., Gay, F., Botto, B., Frairia, C., Evangelista, A., Morabito, F., Boccadoro, M., et al. (2010) · Cancer · doi:10.1002/cncr.25743 · Cited by 15
Farag, S. A., Jeker, B., Bacher, U., Taleghani, B. M., Mueller, B. U., Novak, U., & Pabst, T. (2018) · Hematological Oncology · doi:10.1002/hon.2546 · Cited by 15
“Autologous stem cell transplantation may be single or tandem, while it remains a matter of continued debate how best to routinely incorporate a tandem transplant in the treatment algorithm of myeloma patients.(22,29,30) Whereas the IMWG criteria suggest an ASCT2 in those patients who fail to achieve a VGPR after ASCT,…”
BackgroundGagelmann, N., Eikema, D.-J., de Wreede, L. C., Rambaldi, A., Iacobelli, S., Köster, L., Caillot, D., Blaise, D., Remémyi, P., Bulabois, C., et al. (2020) · Bone Marrow Transplantation · doi:10.1038/s41409-020-01007-w · Cited by 16
“Using a tandem transplantation approach to increase dose intensity and to deepen response has been introduced to the MM treatment sequence >20 years ago, with several phase 3 trials demonstrating improvement in PFS, especially in patients who did not achieve complete remission after first autologous transplantation [1…”
MethodSelf-citationPawarode, A., Mineishi, S., Reddy, P. R., Braun, T., Khaled, Y. A., Choi, S. W., Magenau, J. M., Harris, A. C., Connelly, J. A., Kitko, C. L., et al. (2015) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2015.07.021 · Cited by 16
“First-line consolidative high-dose therapy and autologous (Auto) hematopoietic cell transplantation (HCT) have been shown to prolong myeloma progression [2-4] and are currently considered a standard of care [5,6].”
BackgroundBiology and Treatment of Multiple Myeloma
Tosi, P., Gamberi, B., & Giuliani, N. (2006) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2005.09.008 · Cited by 15
D’Sa, S., Yong, K., Kyriakou, C., Bhattacharya, S., Peggs, K. S., Foulkes, B., Watts, M., Ings, S. J., Ardeshna, K. M., Goldstone, A. H., et al. (2004) · British Journal of Haematology · doi:10.1111/j.1365-2141.2004.04981.x · Cited by 15
“…with an event-free survival (EFS) of 24–30 months (Anderson et al, 1993; Cunningham et al, 1994) and a second transplant may further improve EFS and overall survival (OS), especially in patients who fail to achieve a very good partial response (PR) after the first transplant (Attal et al, 2003).”
BackgroundOverview of drug therapy for multiple myeloma
Saunders, G. (2005) · Journal of Oncology Pharmacy Practice · doi:10.1191/1078155205jp160oa · Cited by 15
Multiple Myeloma, 2004 — One or Two Transplants?
Stadtmauer, E. A. (2003) · New England Journal of Medicine · doi:10.1056/nejme038187 · Cited by 15
Stem cell transplantation for multiple myeloma: current and future status
Giralt, S., & Bensinger, W. (2013) · Leukemia Supplements · doi:10.1038/leusup.2013.3 · Cited by 14
Optimizing high dose melphalan
Shah, G. L., Giralt, S., & Dahi, P. B. (2023) · Blood Reviews · doi:10.1016/j.blre.2023.101162 · Cited by 16
Martino, M. V., Postorino, M., Gallo, G. A., Messina, G., Neri, S., Piro, E., Gentile, M., Moscato, T., Monteleone, R., Fedele, R., et al. (2013) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2013.11.009 · Cited by 14
Doo, N. W., Thompson, P. A., Prince, H. M., Seymour, J. F., Ritchie, D., Stokes, K. H., Burbury, K., Wolf, M. M., Joyce, T., & Harrison, S. J. (2012) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428194.2012.746682 · Cited by 14
Union of forces advances myeloma care
Stewart, A. K. (2010) · Blood · doi:10.1182/blood-2010-04-281212 · Cited by 14
The role of tandem stem cell transplantation for multiple myeloma patients
Martino, M. V., Recchia, A. G., Fedele, R., Neri, S., Vincelli, I. D., Moscato, T., Gentile, M., & Morabito, F. (2015) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2016.1136285 · Cited by 16
“In two studies of tandem ASCT, post hoc subgroup analyses showed that the second procedure improved clinical outcomes in those patients who failed high-quality responses after the first ASCT.[34,35] The International Myeloma Working Group suggests considering timely second ASCT in those patients who fail to achieve a…”
BackgroundMethodResultInfluentialHari, P., Reece, D. E., Randhawa, J. K., Flomenberg, N., Howard, D. S., Badros, A. Z., Rapoport, A. P., Meisenberg, B. R., Filicko-O'Hara, J. E., Phillips, G. L., et al. (2018) · Bone Marrow Transplantation · doi:10.1038/s41409-018-0261-y · Cited by 14
Rifkin, R. M., Jagannath, S., Durie, B. G. M., Narang, M., Terebelo, H. R., Gasparetto, C., TOOMEY, K. E., Hardin, J. W., Wagner, L. I., Parikh, K., et al. (2018) · Clinical Therapeutics · doi:10.1016/j.clinthera.2018.05.017 · Cited by 14
“Age Median (range), y 60 (27 75) 60 (24 74) 60 (24 78) Group <65 y 113 (68) 127 (71) 171 (67) 65 <75 y 51 (31) 53 (29) 82 (32) Male 93 (56) 108 (60) 159 (62) Race White 139 (84) 152 (84) 221 (86) Black 18 (11) 22 (12) 27 (11) Asian 1 (1) 0 1 (<1) Other 1 (1) 2 (1) 2 (1) Not specified 6 (4) 4 (2) 5 (2) ECOG PS 0 or 1 1…”
Multiple myeloma: treatment evolution
Miguel, J. F. S., Mateos, M., Ocio, E. M., & García‐Sánz, R. (2012) · Hematology · doi:10.1179/102453312x13336169154971 · Cited by 16
Harousseau, J. (2007) · Bone Marrow Transplantation · doi:10.1038/sj.bmt.1705810 · Cited by 15
Self-citationManier, S., & Leleu, X. P. (2011) · Immuno-analyse & Biologie Spécialisée · doi:10.1016/j.immbio.2011.04.001 · Cited by 32
Complete response in myeloma: a Trojan horse?
Barlogie, B., & Tricot, G. J. K. (2006) · Blood · doi:10.1182/blood-2006-07-034538 · Cited by 14
Takahashi, S., Aiba, K., Ito, Y., Hatake, K., Nakane, M., Kobayashi, T., Minowa, S., Shibata, H., Mitsuhashi, J., Tsukahara, S., et al. (2007) · Cancer Science · doi:10.1111/j.1349-7006.2007.00571.x · Cited by 14
Activity Survey and Historical Perspective of Autologous Stem Cell Transplantation in Europe
Gratwohl, A. A. (2007) · Seminars in Hematology · doi:10.1053/j.seminhematol.2007.09.001 · Cited by 14
Stem Cell Transplantation in Multiple Myeloma
Attal, M., Moreau, P., Avet‐Loiseau, H., & Harousseau, J. (2007) · Hematology · doi:10.1182/asheducation-2007.1.311 · Cited by 17
Self-citationTariman, J. D., & Estrella, S. M. (2005) · Oncology nursing forum · doi:10.1188/05.onf.e127-e138 · Cited by 14
“However, tandem autologous SCT is recommended for patients who have responded to the first autologous SCT but are not in complete remission or are near a complete response (Attal et al., 2003).”
InfluentialMel, S. D., Chen, Y., Gopalakrishnan, S., Ooi, M. G. M., Teo, C., Tan, D., Teo, M., Tso, A. C. Y., Lee, L. Y. K., Nagarajan, C., et al. (2017) · Singapore Medical Journal · doi:10.11622/smedj.2016150 · Cited by 14
Rossi, G., Falcone, A. P., Minervini, M. M., Cillis, G. P. D., de Waure, C., Sisti, L. G., Giambra, V., Valente, D., Chiello, V., Scalzulli, P. R., et al. (2018) · Cytometry Part B Clinical Cytometry · doi:10.1002/cyto.b.21755 · Cited by 15
Results of autologous and allogeneic hematopoietic cell transplant therapy for multiple myeloma
Arora, M., McGlave, P. B., Burns, L. J., Miller, J. S., Barke, J. N., DeFor, T. E., & Weisdorf, D. J. (2005) · Bone Marrow Transplantation · doi:10.1038/sj.bmt.1704968 · Cited by 14
An update of novel therapeutic approaches for multiple myeloma
Richardson, P. G. G., Hideshima, T., & Anderson, K. C. (2004) · Current Treatment Options in Oncology · doi:10.1007/s11864-004-0014-6 · Cited by 17
Initial treatment of transplant-eligible patients in multiple myeloma
Rosiñol, L., Kumar, S. K., Moreau, P., & Cavo, M. (2014) · Expert Review of Hematology · doi:10.1586/17474086.2014.871200 · Cited by 14
“Two trials showed that patients not achieving at least a VGPR after the first procedure are those who most benefit of the second ASCT [42,45], but these data should be confirmed in prospective studies, using induction therapy based on the new drugs and using standard pre-transplant conditioning regimens (Mel-200).”
BackgroundResultSahebi, F., Shen, Y., Thomas, S. H., Rincon, A., Murata‐Collins, J. L., Palmer, J. M., Krishnan, A. Y., Karanes, C., Htut, M., Somlo, G., et al. (2012) · British Journal of Haematology · doi:10.1111/bjh.12123 · Cited by 14
“Randomized comparisons of single versus double auto-HCT demonstrate superior eventfree survivals in patients treated with tandem auto-HCT, but most patients eventually relapse despite improvements in disease control (Attal et al, 2003; Cavo et al, 2007).”
BackgroundTakimoto, M., Ogawa, K., Kato, Y., SAITO, T., Suzuki, T., Irei, M., Shibuya, Y., Suzuki, Y., Kato, M., Inoue, Y., et al. (2008) · International Journal of Hematology · doi:10.1007/s12185-008-0039-x · Cited by 13
“6 46,XX [4]”
Kauer, J., Freundt, E. P., Schmitt, A., Weinhold, N., Mai, E. K., Müller‐Tidow, C., Goldschmidt, H., Raab, M. S., Kriegsmann, K., & Sauer, S. (2023) · BMC Cancer · doi:10.1186/s12885-023-11507-9 · Cited by 14
Metadata
- Authors
- Attal, M., Harousseau, J.-L., Facon, T., Guilhot, F., Doyen, C., Fuzibet, J.-G., Monconduit, M., Hulin, C., Caillot, D., Bouabdallah, R., Voillat, L., Sotto, J.-J., Grosbois, B., & Bataille, R.
- Affiliations
- Hôpital Purpan (FR)
- Hôpital Claude Huriez (FR)
- Centre Hospitalier Universitaire de Poitiers (FR)
- Centre Hospitalier Universitaire de Nice (FR)
- Centre Henri Becquerel (FR)
- Centre Hospitalier Régional et Universitaire de Nancy (FR)
- CHU Dijon Bourgogne (FR)
- Centre Hospitalier Universitaire de Besançon (FR)
- Hôpital Albert Michallon (FR)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2003-12-25
- Volume
- 349
- Issue
- 26
- Pages
- 2495-2502
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W1982499121
- Cited by
- 984
- References
- 16
- Citations by year
- 2026: 3 · 2025: 13 · 2024: 18 · 2023: 14 · 2022: 22 · 2021: 20 · 2020: 33 · 2019: 18 · 2018: 35 · 2017: 28 · 2016: 24 · 2015: 37 · 2014: 38 · 2013: 53 · 2012: 42
- FWCI
- 34.51
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Digital Access to Libraries (submittedVersion)
- Topics
- Health Sciences › Medicine › Hematology › Multiple Myeloma Research and Treatments
- Health Sciences › Medicine › Hematology › Hematopoietic Stem Cell Transplantation
- Health Sciences › Medicine › Clinical Neurology › Multiple Sclerosis Research Studies
- Keywords
- multiple myeloma, autologous stem cell transplantation, high-dose chemotherapy, overall survival, event-free survival, very good partial response, beta2-microglobulin, lactate dehydrogenase, prognostic factors
- MeSH terms
- Antineoplastic Combined Chemotherapy Protocols, Combined Modality Therapy, Dexamethasone, Doxorubicin, Female, Humans, Male, Middle Aged, Multiple Myeloma, Neoplasm Staging, Prognosis, Transplantation, Autologous, Vincristine, Survival Rate, Multivariate Analysis, Hematopoietic Stem Cell Transplantation, Disease-Free Survival, Transplantation Conditioning
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.